Shares of Nevro Corp. (NYSE:NVRO – Get Free Report) have been assigned a consensus recommendation of “Reduce” from the fourteen research firms that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation and eleven have assigned a hold recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $10.63.
NVRO has been the topic of several research reports. StockNews.com downgraded shares of Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, August 21st. Robert W. Baird dropped their target price on Nevro from $11.00 to $8.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Wolfe Research upgraded Nevro from an “underperform” rating to a “peer perform” rating in a report on Thursday, August 8th. Morgan Stanley dropped their price objective on shares of Nevro from $14.00 to $9.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Finally, JMP Securities downgraded shares of Nevro from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 7th.
Get Our Latest Research Report on NVRO
Institutional Investors Weigh In On Nevro
Nevro Trading Up 13.5 %
NVRO stock opened at $5.79 on Monday. Nevro has a 52-week low of $4.38 and a 52-week high of $22.64. The company has a quick ratio of 3.53, a current ratio of 4.77 and a debt-to-equity ratio of 0.66. The firm has a market cap of $215.85 million, a P/E ratio of -2.53 and a beta of 0.94. The company’s 50-day simple moving average is $7.16 and its 200-day simple moving average is $9.89.
Nevro (NYSE:NVRO – Get Free Report) last released its earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.10. The business had revenue of $104.16 million during the quarter, compared to analysts’ expectations of $107.11 million. Nevro had a negative net margin of 18.17% and a negative return on equity of 24.89%. The company’s quarterly revenue was down 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.69) earnings per share. As a group, equities analysts forecast that Nevro will post -2.6 EPS for the current fiscal year.
About Nevro
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.
Featured Stories
- Five stocks we like better than Nevro
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- ESG Stocks, What Investors Should Know
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is the Australian Securities Exchange (ASX)
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.